Boston Scientific to Acquire Devoro Medical

September 21, 2021—Boston Scientific Corporation announced an agreement to acquire Devoro Medical, Inc., developer of the Wolf thrombectomy platform. The nonconsole and lytic-free Wolf technology targets and rapidly captures blood clots using prongs that retrieve and remove thrombi in the arterial and venous systems.

Michael R. Jaff, DO, Chief Medical Officer and Vice President of Clinical Affairs, Technology and Innovation, Peripheral Interventions, Boston Scientific, commented in the announcement, “The Wolf platform is a compelling new option for physicians performing thrombectomy procedures and, importantly, it is designed to target and remove clots without damaging blood vessels, while also minimizing blood-loss, which may improve outcomes.”

Dr. Jaff added, “We look forward to accelerating the progress of this platform technology so that we help patients who are dealing with these common, yet challenging health conditions.”

Jeff Mirviss, Executive Vice President and President, Peripheral Interventions, Boston Scientific, stated in the press release, “The addition of the Wolf platform advances our efforts to ensure physicians have the right tools to improve procedural efficiencies. Clot management remains a core focus of our business, and upon commercialization, this highly differentiated technology will complement and expand our offerings to a full suite of interventional strategies for thromboemboli, which also includes the EkoSonic endovascular system (EKOS) and the AngioJet thrombectomy system.”

Boston Scientific advised that it has been a strategic investor in Devoro Medical since 2019 and currently holds an equity stake of approximately 16%. The current transaction consists of an upfront payment of approximately $269 million for the remaining 84% stake and up to $67 million upon achievement of certain clinical and regulatory milestones. The transaction is anticipated to close in the fourth quarter of 2021, subject to customary closing conditions.